---
title: "GHRP-2 + Ipamorelin Blend"
canonical_url: https://peptidelibrary.app/library/ghrp2-ipamorelin-combo
description: "Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# GHRP-2 + Ipamorelin Blend

GHRP-2 + Ipamorelin Blend (also called Dual GHS blend) is a research peptide in the Growth Hormone Secretagogue class. This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy.

Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.

Also known as: Dual GHS blend.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: GHS combination / research
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy. The practical consequence is that the profile shifts toward that of the less selective component: GHRP-2 raises ACTH, cortisol and prolactin more than ipamorelin does, so the combination tends to carry more of those effects than ipamorelin alone while offering no new pharmacological pathway. No controlled human data exists for this specific combination.

Targets: GHSR.

Origin: Combination of two synthetic GHRPs.

## Properties

- Molecular formula: Mixture of C45H55N9O6 (GHRP-2) and C38H49N9O5 (Ipamorelin)
- Molecular weight: Mixture
- Half-life: Short; both ~1–2 h combined activity

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010. 2010. Human study (early or uncontrolled). Population: 10 healthy men, tested fasting and non-fasting. Growth hormone, ACTH and prolactin rose, with higher peaks when fasting; vasopressin was not stimulated. Research on a related compound, not this one. Limitations: Studied an analog, not GHRP-2 + Ipamorelin Blend itself [Source](https://pubmed.ncbi.nlm.nih.gov/19907099/)
2. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. 1999. Human study (early or uncontrolled). Population: Healthy male volunteers, 8 per dose level. Dose-proportional pharmacokinetics, terminal half-life about 2 hours, and a single episode of growth hormone release at every dose. Research on a related compound, not this one. Limitations: Studied an analog, not GHRP-2 + Ipamorelin Blend itself [Source](https://pubmed.ncbi.nlm.nih.gov/10496658/)
3. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. 2014. Human study (early or uncontrolled). Population: Adults after small or large bowel resection (117 enrolled, 114 analysed). No significant difference from placebo in time to first tolerated solid meal (p = 0.15). Research on a related compound, not this one. Limitations: Studied an analog, not GHRP-2 + Ipamorelin Blend itself [Source](https://pubmed.ncbi.nlm.nih.gov/25331030/)

## Safety

Side effects: Hunger; Cortisol/prolactin rise from GHRP-2; Water retention.

Risks: WADA S2.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

GHRP-2 + Ipamorelin Blend is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is GHRP-2 + Ipamorelin Blend?

Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.

### How does GHRP-2 + Ipamorelin Blend work?

This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy.

### Is GHRP-2 + Ipamorelin Blend FDA approved?

No. GHRP-2 + Ipamorelin Blend is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of GHRP-2 + Ipamorelin Blend?

Reported half-life for GHRP-2 + Ipamorelin Blend is Short; both ~1–2 h combined activity. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is GHRP-2 + Ipamorelin Blend banned in sport?

GHRP-2 + Ipamorelin Blend is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to GHRP-2 + Ipamorelin Blend?

Compounds most often compared with GHRP-2 + Ipamorelin Blend include Ipamorelin, GHRP-6, GHRP-1 and Pralmorelin (GHRP-2). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Component evidence (Pralmorelin (GHRP-2)) — Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN](https://pubmed.ncbi.nlm.nih.gov/15230633/)
- [Component evidence (Pralmorelin (GHRP-2)) — Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial](https://pubmed.ncbi.nlm.nih.gov/30051972/)
- [Component evidence (Ipamorelin) — The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus](https://pubmed.ncbi.nlm.nih.gov/38996787/)
- [Component evidence (Ipamorelin) — The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism](https://pubmed.ncbi.nlm.nih.gov/39043357/)
